1. Home
  2. RLMD vs BOW Comparison

RLMD vs BOW Comparison

Compare RLMD & BOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.69

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$29.77

Market Cap

734.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
BOW
Founded
2004
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
661.9M
734.3M
IPO Year
2012
2024

Fundamental Metrics

Financial Performance
Metric
RLMD
BOW
Price
$6.69
$29.77
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$12.40
$32.29
AVG Volume (30 Days)
1.5M
138.5K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
45.28
23.26
EPS
N/A
0.48
Revenue
$13,070.00
$551,589,000.00
Revenue This Year
N/A
$21.31
Revenue Next Year
N/A
$19.15
P/E Ratio
N/A
$58.88
Revenue Growth
154.83
29.58
52 Week Low
$0.55
$21.21
52 Week High
$8.00
$37.98

Technical Indicators

Market Signals
Indicator
RLMD
BOW
Relative Strength Index (RSI) 47.20 67.48
Support Level $6.17 $23.65
Resistance Level $7.46 N/A
Average True Range (ATR) 0.45 1.01
MACD 0.03 0.23
Stochastic Oscillator 60.47 96.69

Price Performance

Historical Comparison
RLMD
BOW

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

Share on Social Networks: